In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1432-1041

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients ; day:15 ; month:10 ; year:2021 ; pages:1-13
European journal of clinical pharmacology ; (15.10.2021), 1-13

Creator: Preijers, T.
Spengler, M. W. F. van
Meijer, K.
Fijnvandraat, K.
Fischer, K.
Leebeek, F. W. G.
Cnossen, M. H.
Mathôt, R. A. A.

Contributor: SpringerLink (Online service)

DOI: 10.1007/s00228-021-03173-2

URN: urn:nbn:de:101:1-2021122917550443671946

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:31 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Preijers, T.
Spengler, M. W. F. van
Meijer, K.
Fijnvandraat, K.
Fischer, K.
Leebeek, F. W. G.
Cnossen, M. H.
Mathôt, R. A. A.
SpringerLink (Online service)

Other Objects (12)

Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia

In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates

Circumcision in hemophilia using low quantity of factor concentrates: experience from Dakar, Senegal

The impact of extended half-life versus conventional factor product on hemophilia caregiver burden

Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management

Individualized Dosing of Therapeutic Monoclonal Antibodies—a Changing Treatment Paradigm?

Development of a dosing system for individualized therapy with oral films

OptiDose: Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control

OptiDose : Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control

Individualized dosing of aminoglycosides in neonates: mission accomplished or work in progress?

OptiDose : Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control

Hall of half-life

Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia

In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates

Circumcision in hemophilia using low quantity of factor concentrates: experience from Dakar, Senegal

The impact of extended half-life versus conventional factor product on hemophilia caregiver burden

Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management

Individualized Dosing of Therapeutic Monoclonal Antibodies—a Changing Treatment Paradigm?

Development of a dosing system for individualized therapy with oral films

OptiDose: Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control

OptiDose : Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control

Individualized dosing of aminoglycosides in neonates: mission accomplished or work in progress?

OptiDose : Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control

Hall of half-life

Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia

In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates

Circumcision in hemophilia using low quantity of factor concentrates: experience from Dakar, Senegal

The impact of extended half-life versus conventional factor product on hemophilia caregiver burden

Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management

Individualized Dosing of Therapeutic Monoclonal Antibodies—a Changing Treatment Paradigm?

Development of a dosing system for individualized therapy with oral films

OptiDose: Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control

OptiDose : Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control

Individualized dosing of aminoglycosides in neonates: mission accomplished or work in progress?

OptiDose : Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control

Hall of half-life

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia

In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates

Circumcision in hemophilia using low quantity of factor concentrates: experience from Dakar, Senegal

The impact of extended half-life versus conventional factor product on hemophilia caregiver burden

Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management

Individualized Dosing of Therapeutic Monoclonal Antibodies—a Changing Treatment Paradigm?

Development of a dosing system for individualized therapy with oral films

OptiDose: Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control

OptiDose : Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control

Individualized dosing of aminoglycosides in neonates: mission accomplished or work in progress?

OptiDose : Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control

Hall of half-life

Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia

In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates

Circumcision in hemophilia using low quantity of factor concentrates: experience from Dakar, Senegal

The impact of extended half-life versus conventional factor product on hemophilia caregiver burden

Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management

Individualized Dosing of Therapeutic Monoclonal Antibodies—a Changing Treatment Paradigm?

Development of a dosing system for individualized therapy with oral films

OptiDose: Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control

OptiDose : Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control

Individualized dosing of aminoglycosides in neonates: mission accomplished or work in progress?

OptiDose : Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control

Hall of half-life

Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia

In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates

Circumcision in hemophilia using low quantity of factor concentrates: experience from Dakar, Senegal

The impact of extended half-life versus conventional factor product on hemophilia caregiver burden

Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management

Individualized Dosing of Therapeutic Monoclonal Antibodies—a Changing Treatment Paradigm?

Development of a dosing system for individualized therapy with oral films

OptiDose: Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control

OptiDose : Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control

Individualized dosing of aminoglycosides in neonates: mission accomplished or work in progress?

OptiDose : Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control

Hall of half-life

Related objects

Reset password